AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LumiraDx Ltd

Moderna

Valneva SE

Could health care stocks be the top picks in the stock market this week?

Good Stocks To Buy Right Now? 4 Health Care Stocks For Your List

The FDA gives CRL to AstraZeneca's (AZN) sBLA for Fasenra for chronic rhinosinusitis with nasal polyps (CRSwNP) for want of additional clinical

AstraZeneca's (AZN) Fasenra sBLA for Nasal Polyps Gets CRL

AstraZeneca's (AZN) stock has risen 26.9% in the past year compared with an increase of 22.3% for the industry.

AstraZeneca (AZN) Stock Up 27% in a Year: What Lies Ahead?

Merck

Merck & Co. Inc. MRK, +0.27% said Tuesday that it will stop a clinical trial evaluating Keytruda with AstraZeneca's AZN, +0.15% AZN, -0.76% Lynparza in advanced prostate cancer patients because the combination therapy doesn't work. The company said the drugs did not show an improvement in overall survival, which is one of the trial's primary endpoints.

Merck to stop clinical trial testing Keytruda with AstraZeneca's Lynparza in prostate cancer patients

FDA approves AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated HER2-negative high-risk early breast cancer.

AstraZeneca, Merck's Lynparza Gets FDA Nod for Expanded Use

The Food and Drug Administration's approval on Friday of AstraZeneca's Lynparza as a treatment for some people with early-stage breast cancer could bring in $1.5 billion in annual revenue for the company. U.S.-listed shares of AstraZeneca AZN, +1.38% AZN, +1.20% were up 1.5% in trading on Monday.

SVB Leerink: AstraZeneca's Lynparza could bring in $9.7 billion in sales by 2028

Bristol-Myers

Some cheap stocks are worth investing in.

2 Top Dividend Stocks You Can Buy for Less Than $100 Per Share

Eli Lilly

Pfizer

Sanofi

Can these health care stocks climb this month?

5 Health Care Stocks To Watch In March 2022

Intranasal sprays might be more effective than jabs.

This 1 Innovation Could Disrupt Pfizer and Moderna's Vaccine Supremacy

AstraZeneca (AZN) and Sanofi's (SNY) nirsevimab reduces lower respiratory tract infections like bronchiolitis or pneumonia caused by RSV 74.5% in infants.

AstraZeneca (AZN), Sanofi's (SNY) RSV Vaccine Lowers Infections

The company has the highest gross margin among the top 15 pharmaceutical companies in terms of revenue, which stands at 81.6%.

AstraZeneca: Your Opportunity Is Knocking

AstraZeneca PLC (LSE:AZN) shares jumped this morning after it announced an exclusive US$760mln deal with Neurimmune to develop a drug to combat heart disease. The collaboration and licensing agreement for NI006 will see AstraZeneca's subsidiary Alexion develop, manufacture and commercialise NI006, currently in Phase Ib development for treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).

AstraZeneca and Neurimmune land US$760mln deal for heart disease drug

Inspire Medical Systems Inc

Vertex Pharmaceuticals

Many healthcare stocks have been outperforming the market averages this year. Here are three stocks our roundtable likes.

Don't Tell These 3 Healthcare Stocks There's a Bear Market

GlaxoSmithKline

The FDA authorized an increased dose in the case of AstraZeneca Plc's (NASDAQ: AZN) pre-exposure prophylaxis drug Evusheld (tixagevimab and cilgavimab). "Based on the most recent information and data available, Evusheld may be less active against certain Omicron.

AstraZeneca, GSK's COVID-19 Therapies Lose Efficacy Against Omicron's Subvariants

Novavax

Here are four pharma stocks that looks attractive for the long-term. Deep product development pipelines will ensure steady revenue and cash flow growth.

4 Pharma Stocks to Buy Even if the Pandemic Ends

Chipotle

Enphase Energy

Equinor

STORE Capital

Microsoft

Invesco High Yield Equity Dividend Achievers ETF

Safe stocks tend to perform well no matter what the broader market does. Here are seven defensive companies to research further.

7 Safe Stocks to Buy If You Fear the Bear

AstraZeneca's (AZN) DESTINY-Breast04 is the first-ever phase III study of a HER2-directed therapy to show a statistically significant and clinically meaningful survival benefit in patients with HER2-low metastatic breast cancer.

AstraZeneca (AZN) Enhertu Effective in HER2-Low Breast Cancer

AstraZeneca plc (NASDAQ: AZN) said that Enhertu prolonged survival and slowed the progression of metastatic breast cancer with low levels of a protein known as HER2. Data from the pivotal DESTINY-Breast04 Phase 3 trial showed Enhertu (trastuzumab deruxtecan) demonstrated a.

AstraZeneca's Enhertu Meets Primary Endpoint In HER2-Low Breast Cancer Setting

COVID-19 vaccine maker AstraZeneca said on Tuesday its non-executive chairman Leif Johansson will retire following the annual general meeting next year, and that the search for a successor has begun.

AstraZeneca chairman Leif Johansson to retire in 2023

AstraZeneca PLC AZN, -1.85% AZN, +3.97% and Daiichi Sankyo Co. 4568, +9.55% on Monday reported positive Phase 3 trial results for the Enhertu treatment on breast cancer patients.

Dow Jones Newswires: AstraZeneca Reports ‘Historic' Trial Results for Enhertu Cancer Treatment

AstraZeneca plc (LON: AZN) closed up roughly 4.0% on Monday after the pharmaceutical behemoth said its cancer drug, Enhertu, showed promising results against a type of breast cancer with poor treatment options. Enhertu is effective against HER2-low metastatic breast cancer According to the British multinational, its late-stage clinical trial suggests Enhertu significantly prolongs progression-free survival […] The post AstraZeneca reports promising results for its breast cancer therapy appeared first on Invezz.

AstraZeneca reports promising results for its breast cancer therapy

AstraZeneca PLC (LSE:AZN) reported positive high-level results from its pivotal DESTINY-Breast04 Phase III trial which showed an improved survival rate for patients treated with Enhertu (trastuzumab deruxtecan).  In the trial, Enhertu demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) in patients with HER2-low unresectable and/or metastatic breast cancer regardless of hormone receptor (HR) status versus treatment with chemotherapy, the drug giant said in a statement.

AstraZeneca's Enhertu shown to improve survival in breast cancer patients in pivotal trial

TOKYO & MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU Significantly Improved Both Progression-Free & Overall Survival in DESTINY-Breast04 Trial in Patients with HER2 Low Metastatic Breast Cancer

ENHERTU® Significantly Improved Both Progression-Free and Overall Survival in DESTINY-Breast04 Trial in Patients with HER2 Low Metastatic Breast Cancer

AstraZeneca's (AZN) Saphnelo is the only new biologic to be approved in Europe in over a decade for patients with systemic lupus erythematosus.

AstraZeneca's (AZN) Lupus Drug Saphnelo Gets Europe Nod

According to officials and internal World Health Organization documents reviewed by Reuters, the relatively short shelf life of AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine is complicating the rollout to the world's poorest nations. The need to turn down vaccines with short shelf lives, along with the initial inequality, hesitancy, and other barriers, has contributed to a much lower vaccination rate in Africa, where only around 10% of people have been immunized.

News for AstraZeneca Stock (AZN)